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Greetings from the Senior Associate Dean 
for Research and Graduate Education
G R E E T I N G S
Welcome to the inaugural issue of our Biomedical Sciences magazine, “We Are…  Bridging 
Medicine and Science.”  This magazine will be published annually and will provide both highlights 
and in-depth feature articles about the Biomedical Sciences (BMS) Graduate Program at 
Marshall University’s Joan C. Edwards School of Medicine. 
I would like to thank Miranda Carper, a current Ph.D. candidate, for conceiving of the title for our 
new magazine as part of a contest among our graduate students. The play on the initials for our 
“BMS” program conveys the essence of our mission—research and graduate training that will 
lead to improved treatment of disease. I also want to thank Diana Maue and her student assistant, 
Tamara Trout, who took the lead on turning this concept into reality. This assignment was loaded 
onto Diana’s already demanding workload of recruiting students for our BMS program and 
managing the Summer Research Internship for Minority Students program. 
The BMS program has signi#cantly increased in size, quality, and scope since I arrived at 
Marshall in 1992. In speaking to members of the community and even to some clinical and 
non-medical school faculty, I have found that they are often not aware of our BMS program and its 
accomplishments. These observations, along with the reasons listed below, are the driving factors 
for the launch of this new magazine. Our goals for this publication are:
• To inform alumni, members of the Marshall University community, greater Huntington 
community leaders, and state and federal policymakers about our program and its 
accomplishments;
• To recognize the achievements of BMS faculty and students; and
• To serve as a recruitment tool.
I look forward to sharing our many exciting research projects, and student and infrastructure 
accomplishments. I also welcome any questions, comments or suggestions related to this 
magazine or to our BMS program. Please direct them to me at niles@marshall.edu.
Thank you for taking the time to read our new issue!
Best regards,
Richard M. Niles, Ph.D. 
Senior Associate Dean for Research and Graduate Education
Joan C. Edwards School of Medicine
Marshall University
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New Translational Genomic  Research Institute
Opens its Doors
Miranda Carper, Ph.D. candidate
“We Are… Bridging Medicine and 
Science.”  How true this is now that 
the greatly anticipated construction of 
Marshall’s new Charles H. McKown, Jr., MD 
Translational Genomic Research Institute 
(TGRI) at the Edwards Comprehensive 
Cancer Center is complete. The excitement 
of building a new facility may be winding 
down, but the real reward will come with 
the use of the facility. This new facility, 
occupying 10,500 square feet on the 
third "oor of the cancer center, supports 
the medical school’s basic science 
o#erings and clinical researchers by 
enabling them to rapidly translate 
genome-based laboratory research into 
clinical applications that will improve 
patient care.
by Tamara Trout
The TGRI shares its origins with the cancer 
center. In the midst of Joan Edwards’ 
involvement in the planning of the center, 
Dr. Charles McKown, who was then dean of 
the medical school and a good friend of 
Mrs. Edwards, explained to her the concept 
of translational medicine. She came to the 
conclusion that building an institute dedicated 
to translational research within the center 
would be a critical addition, as it would focus 
on applying biomedical research directly to 
patient care. She allocated additional funds, 
and an extra %oor was consequently added to 
the building plans. 
The late U.S. Senator Robert C. Byrd made the 
completion of the institute possible when he 
obtained $3.9 million in federal funds to 
#nish its development. Conversations with 
Dr. McKown and Dr. Donald Primerano (see 
page 8) led Senator Byrd to recommend that 
the institute focus on genomic research. The 
senator supported their belief that the center’s 
yield for translational research would be found 
in genomics, including the goal of identifying 
the speci#c genes responsible for various 
cancers. James J. Schneider, Senior Associate 
Dean of Finance and Administration for the 
school of medicine, and Dr. Richard Niles, 
Professor/Chair of Biochemistry & Microbiology 
and Senior Associate Dean of Research and 
Graduate Education, were co-investigators 
in writing the proposal to obtain the funds 
Senator Byrd had set aside. 
Now in operation, the TGRI’s primary goal is 
to enable Marshall researchers to conduct a 
greater number of investigator-initiated clinical 
trials. Allowing basic scientists to work in close 
proximity to clinicians will encourage them to 
collaborate, providing new research ideas and 
clinical applications. 
The institute will also provide a new home 
for the cancer research conducted by several 
Biomedical Sciences Graduate Program 
professors. Researchers who work in the 
institute were selected based on two factors:  
their work lends itself to clinical applications 
and they have actively funded grants. The 
professors selected include Dr. Pier Paolo 
Claudio, Dr. W. Elaine Hardman, and Dr. Niles. 
Dr. Claudio is a scientist whose research 
exempli#es the founding vision of the TGRI. 
He studies the e!ects of dietary agents 
on cancer, with emphasis on growth and 
metastasis, and uses targeted gene therapy 
to improve the e+cacy of cancer treatment. 
Dr. Claudio has also recently launched a Phase 
I clinical trial at the TGRI, seeking to determine 
the e!ectiveness of existing chemotherapy 
treatments for patients with small cell lung cancer.
Dr. Hardman, who is widely recognized for 
her work studying the e!ects of omega-3 
fatty acids on the development of cancer, also 
exempli#es the type of researcher the TGRI 
hopes to foster. She has published research 
that indicates that, in animal models, a diet 
high in omega-3 fatty acids can prevent the 
development or slow the growth of multiple 
cancer types. To extend this research to 
humans, Dr. Hardman and medical oncologist 
Dr. Oscar Ballester (Edwards Comprehensive 
Cancer Center), conducted a human clinical 
trial, in which patients with early stage chronic 
lymphocytic leukemia consumed supplemental 
omega-3 fatty acids.
Dr. Niles also conducts groundbreaking 
studies in nutrition and cancer. His research 
focuses on vitamin C and the fact that di!erent 
tissues in the body and various tumors show 
altered ability to take up and use the vitamin 
as a cofactor for enzymatic reactions. 
Dr. Niles and Dr. Sarah Miles, a postdoctoral 
fellow in his laboratory, are involved in a 
translational project with Dr. Jose Pulido, 
an ophthalmologist at the Mayo Clinic. This 
research has led to a provisional patent as a 
diagnostic test and also the use of a treatment, 
which allows the patient to, at least temporally, 
achieve remission of the disease. 
These TGRI researchers will also focus on projects 
that transcend their primary goal of performing 
and applying translational genomic research. 
F E A T U R E  S T O R Y
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Dr. Claudio’s
studies are 
bringing about 
new insights into 
the mechanisms 
behind cancer 
progression. He 
has invested 20 
years in studying 
the molecular 
mechanisms of the transformation 
of malignant tumors. The result is his 
development of a new drug delivery system 
that makes gene therapy safer and more 
e!ective by distributing genes directly to 
diseased tissue via ultrasound.
Phase I of Dr. Hardman’s human clinical 
study has yielded promising initial evidence 
linking omega-3 fatty acids to the halt 
of cancer progression.  She also recently 
published a study in “Nutrition and Cancer” 
that showed that, in mice bred to be 
predisposed to developing breast cancer, 
including walnuts in their diet lowered their 
incidence of developing cancer by 50%.  
Dr. Niles’ laboratory studies the mechanism 
that allows dietary components such as 
resveratrol (found in 
red wine), vitamin 
A, and quercetin 
(found in apples) to 
arrest melanoma cell 
growth and prevent 
melanocytes 
from developing 
into melanoma. 
Melanoma is 
notoriously hard to treat and has a #ve 
year survival rate of 2-3%, and Dr. Niles 
is committed to making discoveries that 
improve patient prognosis.
New Translational Genomic  Research Institute
Spotlight on the
TGRI researchers
Allowing basic scientists to work in close 
proximity to clinicians will encourage them to 
collaborate, giving them all sources for new 
research ideas and clinical applications. 
F E A T U R E  S T O R Y
Dr. W. Elaine Hardman, one of the faculty 
now based at the TGRI.
Namely, the TGRI will also house the West 
Virginia Cancer Genomics Network, which 
includes two members:  Marshall University 
and the Mary Babb Randolph Cancer Center 
at West Virginia University. The network has 
been funded by federal stimulus money, with 
the goal of developing a database of genomic 
information that will allow researchers to 
compare the genes of multiple patients 
su!ering from the same types of cancer. The 
database could help doctors and researchers 
predict response to targeted therapies, and 
identify whether patients at risk of developing 
a condition express the same mutations as 
patients with full-blown cancer. Such patients 
could be targeted to receive more rapid and 
aggressive treatment to help prevent the cancer 
from progressing.
Anyone interested in learning more about the 
TGRI or in contributing to its operations can 
contact Dr. Niles directly at niles@marshall.edu. 
Biomedical Sciences graduate students and 
medical and postdoctoral students who are 
interested in working at the institute may submit 
their résumés to mubiomed@marshall.edu.
 
BMS Medical Sciences Students
Serve in Medical Mission to Honduras
F E A T U R E  S T O R Y
by Tamara Trout
Aaron Dom holds a young boy in Honduras. 
Aaron is a graduate of the BMS Medical Sciences 
program who is now a "rst year student at 
Marshall University School of Medicine.
In a darkened room in the small 
town of Coyolito in Valle, Honduras, 
Dr. Gerald Soltis shines a light into 
the eyes of an elderly man. The man’s 
grandson, appearing to be no more than 
$ve years old, sits apprehensively at his 
side and holds his hand. 
“Can you see the light?” asks Dr. Soltis gently. 
As the man speaks in cracked and hushed 
tones, a translator con#rms that the man is 
unable to see anything, even light. Dr. Soltis 
discovers during his exam that a failed prior 
surgery, meant to save the man’s eyes after 
a head injury, robbed him of whatever sight 
remained. The doctor’s only recourse is to refer 
him to a surgeon in the capital, Tegucigalpa, 
who can hopefully relieve the pressure that is 
causing him great pain.
Such moments are frequently experienced 
on medical brigades. Each year, the Joan C. 
Edwards School of Medicine sends a team 
of doctors and students to serve a medically 
underserved community in Honduras, an 
impoverished country in Central America. 
Although a brigade cannot cure all conditions 
it encounters, such a team can alleviate much 
su!ering and help ensure treatable conditions 
do not lead to permanent injury or death.  
The trip is organized under the umbrella of the 
Global Medical Brigades, a student-led global 
health and sustainable development organization 
that sends more than 3,000 volunteers and 
medical professionals each year to help organize 
mobile medical clinics in communities lacking 
access to basic medical resources.
Most participants of the medical brigade are 
medical students, but graduate students in the 
medical sciences program also are encouraged 
to participate. The program not only furthers 
students’ classroom experience, but also 
commonly exposes them to relevant, hands-on 
experiences in the medical #eld. The medical 
school’s annual mission trip to Honduras is 
a prime example. In the past two years, six 
medical sciences students have chosen to 
participate.
When students travel to Honduras, they are 
departing from a country that provides most 
of its residents with ready access to medical 
care. A quick search for the term “doctor” in 
Huntington, W.Va., on Superpages.com, for 
example, returns about 500 listings. According 
to the University of California Atlas on Global 
Inequality, however, the Republic of Honduras 
provides only a few dozen doctors for a city 
of comparable size. For some people, this 
means living more than 20 miles from a 
doctor—a journey that can take hours due to 
the mountainous landscape. The cost of such 
a trip plus medical care and medications is 
prohibitive, as most families subsist on less 
than two dollars per day.  
Consequently, according to the Global Medical 
Brigades, the most common causes of death in 
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In the past two years, the brigades from 
Marshall have treated more than 2,400 patients 
and distributed more than $26,000 worth of 
medical supplies and medications.
F E A T U R E  S T O R Y
Rotem Elitsur, a former medical sciences student and current medical student,
poses with one of her youngest patients.
Natalie Weaver, an undergraduate student 
at Marshall, tends to a patient in triage.
Honduras are easily preventable and curable 
illnesses such as diarrhea, parasitic infections, 
and even the common cold. Honduras is one of 
the four poorest countries in the Americas, and 
the Pan American Health Organization is seeking 
to #ll in the health gaps within the country. Each 
year, the Marshall medical brigade plays a role in 
helping to reach for this goal.
 
In the past two years, the brigades from 
Marshall have seen more than 2,400 patients 
and distributed more than $26,000 worth of 
medical supplies and medications. During 
both brigades, Dr. Charles Clements, a Marshall 
medical school professor, has accompanied 
the students as the lead physician. Each day 
of the trip, the members of the brigade set 
up a triage, pharmacy, dental station, and eye 
exam room. A typical day on a brigade consists 
of traveling early in the morning to a distant 
village, setting up a mobile clinic by 10 a.m., 
and working tirelessly until the last patient is 
seen. Many patients walk for hours on foot to 
be seen in the clinics, having no other access to 
medical care. 
Medical sciences program graduate students, 
though not yet medical professionals, have 
been able to serve many critical roles in the 
brigade. They are able to complete triage 
questionnaires with patients, take patient vital 
signs, distribute medications at the pharmacy 
and explain their proper use, assist the 
ophthalmologist with eye exams, and serve as 
translators. 
According to Aaron Dom, a 2010 participant, 
this trip not only provided him valuable 
medical experience and assisted him in 
his medical school applications, but also 
underscored his desire to become a physician. 
“It really reinforced why I want to help take care 
of people,” Dom said. 
Another medical sciences student and brigade 
participant, Amy Young, said the most valuable 
lesson she learned on the trip was teamwork. 
Amy’s experiences showed her that “in the #eld 
of medicine, teamwork is essential. When good 
teamwork is involved, patient satisfaction and 
the quality of care that a patient receives is 
tremendous.” 
She discovered that every pair of hands 
available was critical to meeting the needs of 
the patients who had come seeking care. 
In addition to providing medical care, medical 
sciences students have the opportunity to 
provide further assistance to the communities 
they visit. This includes spending time with 
children in schools and orphanages and 
participating in public health projects. 
Medical health brigades are dramatically 
improving the health of the people of 
Honduras. Students who participate in such a 
volunteer project display great empathy, and 
what they experience while on the trip further 
engages their desire to impact the lives of 
patients. These students can only become better 
physicians as a result, and Marshall looks forward 
to sending many more graduate and medical 
students in the future. 
Members of the local medical community 
are welcome to contact the medical school 
regarding participation in or donation to future 
brigades. Eye doctors and dentists are especially 
sought after for this trip; if just one more of 
each joined the next brigade, nearly double the 
number of patients could be seen. For more 
information about participating in 
the brigade in the summer of 2012, contact 
Jacob Kilgore at kilgore14@marshall.edu. 
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Dr. Donald Primerano: 
The Heart of the Genomics Core Facility
F E A T U R E  S T O R Y
As Dr. Donald Primerano recalls joining the Marshall University Biomedical Sciences (BMS) Graduate Program, his eyes light up 
and he says with a smile, “There’s so much good fortune mixed up in it all.”
While Dr. Primerano counts himself fortunate to be teaching and researching at Marshall, his colleagues are thankful for his 
presence on the faculty. The Biomedical Sciences Graduate Program welcomes the opportunity of this inaugural issue to highlight 
Dr. Primerano’s accomplishments in establishing the Genomics Core Facility.
Next-generation sequencer takes lab to next level
This is the story of Dr. Primerano and his service 
to the program, including the development of 
the core facility and its most recent acquisition, 
an Illumina HiSeq1000 Next-Generation 
Sequencer. The sequencer is a cutting-edge 
piece of equipment that has great scienti#c 
and medical signi#cance, and is a superior 
achievement for the program.
Dr. Primerano came to Marshall University 
in 1988 as an Assistant Professor in the 
Joan C. Edwards School of Medicine. When he 
arrived, he intended to continue his research 
on the regulation of spore formation in 
baker’s yeast. However, Dr. Albert Moat (chair 
of Microbiology at the time) encouraged 
him to begin focusing on projects relating to 
human health, a recommendation that led 
him to begin collaborating on human genetics 
projects. His #eld of expertise has grown 
to encompass the genetic susceptibility of 
patients to cardiovascular disease.
In 1990, he established the Genomics Core 
Facility to provide access to instruments 
to aid in the analysis of gene expression. 
The establishment of the facility was made 
possible by a grant from the National Science 
Foundation and the West Virginia Experimental 
Program to Stimulate Competitive Research. 
The grant enabled the purchase of several 
pieces of equipment—two DNA synthesizers, a 
peptide synthesizer, and a protein sequencer—
that were used until 2005. Since that time, 
the facility has developed a reputation for 
providing superior service to its research clients. 
Dr. Primerano’s next funding breakthrough 
came in 2000, when he received a grant 
from the West Virginia IDeA Network of 
Biomedical Research Excellence program to 
establish the Microarray Core Facility, a subset 
of the Genomics Core Facility. Researchers 
in the Microarray Core Facility conduct 
gene expression, protein, and chromatin 
studies. DNA microarray experiments allow 
a researcher to assess the expression status 
of all genes in the human genome in a single 
experiment, markedly accelerating the pace 
of research. The grant funded the acquisition 
of critical equipment, including an Agilent 
microarray scanner, and several real-time 
thermal cyclers. These machines are still 
available in the facility. During this period, 
Jan Sikorski, a BMS graduate student, Dr. Terry 
Fenger, Dr. Jim Denvir, and 
Dr. Primerano used these instruments to 
develop a new method for quantifying 
damage to DNA. 
To further enhance the Genomics Core Facility’s 
o!erings, Dr. Primerano then set his sights 
on obtaining the next-generation sequencer. 
The Illumina HiSeq 1000 was acquired in April, 
and Marshall University is the only university 
in West Virginia that has one. This machine, 
funded by the National Institutes of Health, 
allows scientists to conduct DNA sequencing 
on many types of biological material including 
patient tumor samples. In addition, the 
machine can quantify known mRNA molecules 
and discover new mRNAs. 
This powerful tool holds great bene#t to the 
Marshall research and patient communities 
alike. The power to sequence a genome 
quickly—one of the bene#ts of the next-
generation sequencer—can help doctors 
identify mutations that cause inherited 
diseases and based on that information tailor 
medical interventions to their patients’ unique 
characteristics. For example, a patient with a 
mutation that leads to a highly aggressive form 
of cancer could be identi#ed early and receive 
intensive medical intervention to prevent that 
cancer from progressing to a more deadly state.
The data obtained using the sequencer will 
be cataloged and stored in the recently 
established West Virginia Cancer Genomics 
Donald Primerano, Ph.D.
by Tamara Trout
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Network, which supports a sophisticated 
database of patient information. Sequencing, 
storing, and analyzing the genetic code of 
patients who have su!ered from various 
conditions will yield information critical to 
understanding, preventing, and treating cancer 
in future patients. 
The database will provide valuable information 
about genetic changes in tumors, allow doctors 
to distinguish between cancers, and help 
researchers #nd the precise ways in which 
pharmaceuticals a!ect cancer cells.
Dr. Primerano’s own research directly impacts 
the health of patients in our region. He is 
primarily interested in discovering the ways 
in which patients’ genetics render them 
susceptible to complex diseases such as 
obesity, stroke, diabetes, and cardiovascular 
disease. Also, Dr. Primerano plans to use the 
next-generation sequencer to identify genetic 
variants that lead to an inherited lipid disease 
called Familial Combined Hyperlipidemia. His 
interest in these conditions and his expertise 
have led him to assume the role of director 
of the Appalachian Cardiovascular Research 
Network (ACoRN). 
Now the head of the Division of Microbiology, 
Dr. Primerano has lectured in medical 
microbiology, human genetics, nucleic acids/
protein synthesis, and molecular and cell 
biology. He has served as a professor of 
distinction and has received multiple awards 
during his service at Marshall, including 
Professor of the Year and the Certi#cate of 
Teaching Excellence. 
The BMS Graduate Program is thankful to 
Dr. Primerano for his years of service to 
Marshall University and for considerably 
growing its research infrastructure. For 
more information about the Genomics Core 
Facility, please visit http://bms.marshall.edu/
core_facilities. 
The next-generation sequencer can 
sequence genomes quickly, which can help 
doctors to identify mutations that cause inherited 
diseases, and tailor medical interpretations to 
their patients’ unique characteristics.
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HIGHLIGHTS:
• Maximum output: 300GB
• Maximum reads: 750 million total, 
94 million per lane
• Maximum paired-end reads: 
 1.5 billion, 188 million per lane
• Required input: 100 ng
• Read length: 2x150 bp
• Percentage of bases > QD 30: 
>85% (2x50 bp); >80% (2x100bp)
WHAT DOES THIS MEAN TO 
THE LAY PERSON?
• The Illumina HiSeq 1000 allows 
individual labs to process more 
DNA samples at once and to 
study  genomes that are larger 
and more complex at a lower 
cost. It also o!ers the ability 
to upgrade, should future 
sequencing needs of the lab 
increase.
• The next-generation sequencer 
can examine an entire genome 
and identify all of the mRNAs 
expressed in a cell line and query 
speci#c mRNAs.
• At its maximum capacity, the 
sequencer can generate 10GB 
data in a 10-day period. Since 
 the human genome consists of 
 3 billion bases, theoretically, 
 33 genomes could be analyzed 
at once in 10 days. However, 
scienti#c testing always requires 
taking potential error into 
account. To ensure the accuracy 
of results, testing usually includes 
using only one person’s genome 
and testing it 30 to 40 times 
simultaneously. 
TO PUT THE SCALE OF GENOME 
PROCESSING INTO PERSPECTIVE:
• One person’s genome consists of 
20-25,000 genes that encode for 
proteins, in addition to DNA that 
does not code for proteins. 
• The genome contains about 
 3 billion base pairs, the equivalent 
of enough information to #ll 
200 volumes of books the size 
of Manhattan city phone books 
(about 1,000 pages in length each).
• Sequencing an entire human 
genome the #rst time cost 
many millions of dollars and 
took nearly 13 years.  With 
instruments such as this, whole 
genome sequencing now costs 
around $10,000 to $20,000 and is 
completed in a matter of days.
• Scientists like Dr. Primerano seek 
to make the cost of sequencing 
a patient’s genome $1,000 or 
less, making whole genome 
sequencing possible for everyone 
who needs it.
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Dr. Maria Serrat is new 
to the Department of 
Anatomy and Pathology, 
joining Marshall from 
Cornell University. 
She researches the 
e!ects of temperature 
and exercise on 
bone physiology and 
serves within both 
the Neuroscience and 
Developmental Biology, and Toxicology and 
Environmental Health Sciences clusters.
Dr. James “Jim” Denvir joined Marshall’s 
Biomedical Sciences faculty from West Virginia 
University in the 
summer of 2011 as 
the Bioinformatics and 
Statistical Analyst. 
Dr. Denvir will conduct 
some research, but 
will apply most of his 
expertise to the Genomics 
Core Facility and teaching 
the Biostatistics class, 
which is designed 
speci#cally for Biomedical Sciences research 
students. 
Dr. Emine Koc joined 
the Department of 
Biochemistry and 
Microbiology from 
The Pennsylvania State 
University in summer 2011. 
Her research will be within 
two BMS clusters:  Cancer 
Biology and Cardiovascular 
Disease, Obesity and 
Diabetes.
Dr. Ernest M. 
“Ernie” Walker, Jr., 
passed away in June 
2010. Dr. Walker joined 
the faculty at Marshall 
University in 1992 
from the University of 
Arkansas for Medical 
Sciences, continuing 
a career devoted to 
academic medicine. 
His field of specialty was heavy metal 
toxicity and iron overload research, and he 
taught as a Professor of Pathology, with five 
years of service as the 
Department Chair.
Dr. Todd L. Green 
completed his first 
year as Biomedical 
Sciences Director of 
Graduate Studies. He 
is also the advisor to 
the first-year medical 
sciences students.
Dr. Wei-ping Zeng joined Marshall from 
the University of Rochester last fall. 
Dr. Zeng researches 
within the Infectious 
and Immunological 
Diseases research 
cluster. His area of 
expertise is cellular 
immunology and the 
involvement of the 
immune system in 
chronic diseases.  
This past year has marked the beginning 
of a transition period for the Biomedical 
Sciences (BMS) Graduate Program. 
The “baby-boomer” generation is 
approaching retirement, and the 
program is starting to see this transition 
in its faculty. Dr. Vern Reichenbecher 
and Dr. Mike Moore retired at the end 
of this past academic year. While the 
program will lose the expertise and 
experience of these 
faculty members, 
this presents the 
opportunity for 
younger faculty to 
move into leadership 
roles.
The second major 
transition was the 
new requirement for 
faculty to assume 
responsibility for 50 percent of the 
graduate assistantship stipend of Ph.D. 
students beginning their third year. 
As a result of this policy, which was 
implemented July 1, the number of 
predoctoral fellowship grant applications 
obtained this current academic year has 
increased by a little more than two-
fold over last year. A number of these 
applications have already been funded. 
This outcome bene"ts not only the BMS 
program, but also its students, who can 
now list this honor on their CVs.
The BMS program has made signi"cant 
improvements over the past "ve 
years in the number, quality, and 
accomplishments of its graduate 
students, as well as the teaching and 
research accomplishments of its faculty. 
The challenge for the next several 
years is to maintain and enhance these 
improvements.
Dr. Mike Moore
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Grant Funding for the 2010 - 2011 Academic Year
Admissions Report
Summer Research Internship for Minority Students
NUMBER OF COMPETITIVE GRANT APPLICATIONS | 35
AMOUNT OF FUNDS REQUESTED | $25,830,024
NUMBER OF COMPETITIVE GRANTS FUNDED | 24
AMOUNT OF FUNDING | $1,575,841
The total amount of funding for AY 2010-11 (competitive + non-competitive) = $9,969,077.
A major success this past academic year was our partnering with the University of 
Kentucky for its Clinical and Translational Sciences Award (CTSA) application. The 
submission received an excellent score and the NIH announced that it would be 
funded in June 2011. The timing ties in nicely with the imminent occupancy of the 
Charles H. McKown, Jr., MD Translational Genomic Research Institute located in the top 
%oor of the Edwards Cancer Center. This partnership will allow our faculty to compete for 
pilot grant funding available through the CTSA and for training opportunities in clinical 
and translational research.
The BMS Graduate Program has a commitment to diversify its student body and 
is pleased to announce the Summer Research Internship for Minority Students 
(SRIMS). It is hoped this program will not only help establish a pipeline of minority 
students entering health-related research #elds, but also enrich our current 
biomedical sciences research o!erings through an added diversity of ideas, 
perspectives, and cultures.
SRIMS is a nine-week internship that gives underrepresented minorities the 
opportunity to conduct graduate-level biomedical research. Participants receive 
formal research training while expanding their learning experience through 
workshops, seminars, and mentoring. Each participant receives travel assistance, 
free room and board, and a $3,000 stipend. During the last week of the program, 
all students present their research at the West Virginia Summer Research 
Symposium. 
This summer was the program’s third year, and participants came from New 
Hudson, Michigan; Charles Town, West Virginia; Carbondale, Illinois; and Ravenna, 
Ohio. For more information, visit http://bms.marshall.edu/srims or send inquiries 
to srims@marshall.edu.
SRIMS is a nine-week internship 
that gives underrepresented minorities 
the opportunity to conduct 
graduate-level biomedical research.
The number of applications to the 
BMS M.S., Medical Sciences, program 
doubled between 2007-08 and 
2009-10. The acceptance of the 
medical sciences students into 
allopathic or osteopathic medical 
schools remains between 71 and 90 
percent, depending on the class year. 
Although approximately the same 
number of students applied to the 
Ph.D. program as compared to the 
previous year, the applications 
were impressive, and all $ve of the 
admission committee’s top choices 
accepted o#ers of admission and 
matriculated in the fall of 2009. 
Amber Mills, 
2011 SRIMS participant
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gave 31 poster and oral presentations at a 
variety of scienti#c meetings this year, and the 
faculty holds 12 extramurally funded grants. 
Of additional note, Dr. Nalini Santanam was 
invited to present her research in the area 
of endometriosis at several special seminar 
presentations, to speak at an international 
conference on free radicals, and to speak about 
obesity at the Appalachian Health Summit.
The Cancer Biology Research Cluster 
includes three postdoctoral fellows and nine 
faculty members who mentored 13 Ph.D. 
students, four of whom received their degrees 
this past year. Also, faculty mentored 10 M.S. 
research, 10 undergraduate, and three medical 
students. Faculty 
members authored 
27 papers and three 
book chapters and 
presented at 10 
meetings. One West 
Virginia State (pilot) 
grant, one foundation 
grant, and nine federal 
grants were awarded 
to cluster faculty. Of 
particular note 
is the research of Dr. W. Elaine Hardman 
and Dr. Philippe Georgel on omega-3 fatty 
acids, epigenetics, and breast cancer, funded 
by the Department of Defense. Their work 
was recently presented at the “Era of Hope” 
meeting in Orlando and was selected for 
special press coverage. To learn more about 
Cancer Biology faculty and their research, 
read the article “New Translational Genomic 
Research Institute Opens its Doors.” 
Toxicology and 
Environmental Health 
Sciences has eight 
faculty members, six 
graduate students, 
and a number of 
medical students 
and undergraduates. 
Of recent note was 
Dr. Piyali Dasgupta’s 
invitation to speak at a 
Nicotine Replacement 
Therapy Meeting, organized by the Food and 
Drug Administration. She was also honored 
with the Marshall University John and 
Frances Rucker Graduate Advisory Award 
for 2011. Additionally, Mike Brown, a Ph.D. 
candidate in Dr. Monica Valentovic’s lab, won 
the BMS Award for Best Overall Performance, 
which funded his recent trip to present at the 
Lipid Biology and Lipotoxicity Symposium in 
Kerry, Ireland. 
Neuroscience and 
Developmental 
Biology has seven 
primary and nine 
secondary faculty 
members, three Ph.D. 
students, three BMS 
Master’s research 
students, nine 
Biological Sciences 
Master’s students, 
and several undergraduate students. This year, 
faculty had two book chapters, two review 
papers and seven primary peer-reviewed 
articles published. Two new extramural grants 
were awarded, added to #ve already ongoing 
NIH-, NASA-, and NSF-funded grants. Dr. Sasha 
Zill gave seminars at Case Western Reserve 
University and in Bielefeld and Cologne 
Germany. Additionally, Dr. Maria Serrat was 
selected as a participant in the United States 
Bone and Joint Decade Young Investigator 
Initiative. 
Molecular Mechanisms 
of Pathogenesis 
changed its name in 
2011 to Infectious 
and Immunological 
Diseases to better 
re%ect the research 
activities of its members. 
The cluster currently 
includes #ve faculty 
members and two 
Ph.D. students, who 
collectively held nine funded grants and 
released seven peer-reviewed publications. 
Melinda “Mindy” Varney, a Ph.D. candidate in 
Dr. Vincent Sollar’s lab who recently 
earned her Ph.D., was the #rst-place 
winner for the statewide graduate 
student research competition at the 
2010 STaR Symposium.
Cardiovascular Disease, Obesity 
and Diabetes Research Cluster 
(CODRC) has 14 faculty members, four 
Ph.D. students, one M.S. student, two 
postdoctoral 
fellows, 
three clinical 
fellows, and 
a number of 
undergraduate 
and medical 
students. 
CODRC faculty 
and their 
students 
Recognizing that science today 
is increasingly crossing traditional 
departmental boundaries, 
Marshall University’s Biomedical Sciences 
(BMS) Graduate Program takes an 
interdisciplinary approach and organizes 
its faculty into the following research 
groups, also referred to as “research 
clusters:”  Toxicology and Environmental 
Health Sciences; Neuroscience and 
Developmental Biology; Infectious and 
Immunological Diseases; Cardiovascular 
Disease, Obesity and Diabetes;  
and Cancer Biology.
The research clusters were organized 
according to the key areas of faculty 
research expertise and are available 
to students pursuing the M.S. 
or Ph.D. degree.
Monica Valentovic, Ph.D.
Simon Collier, Ph.D.
Hongwei Yu, Ph.D.
Nalini Santanam, Ph.D.
Beverly Delidow, Ph.D.
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Melinda Varney, 
Ph.D. – Dr. Varney 
earned her Ph.D. in 
December 2010 under 
the mentorship of 
Dr. Vincent E. Sollars. 
She is working 
in the Division 
of Experimental 
Hematology and 
Cancer Biology at 
Cincinnati Children’s Hospital Medical 
Center in Cincinnati, Ohio. Her research 
focuses on modifiers of TRAF6 and their 
contributions to Myelodysplastic 
Syndromes (MDS).
Jasjeet Bhullar, 
Ph.D. – Dr. Bhullar 
earned her Ph.D. in 
May 2011 under 
the mentorship of 
Dr. Vincent E. Sollars. 
She is caring for her 
new son and living in 
Bethesda, Maryland.
Yue Huang, Ph.D. 
– Dr. Huang earned 
his Ph.D. in May 2011 
under the mentorship 
of Dr. Guo-Zhang 
Zhu. He is working as 
Postdoctoral Fellow 
in the Department of 
Oncological Sciences 
at Mount Sinai School 
of Medicine in New 
York, New York. His 
research project is to study epigenetic 
regulation in hematopoietic stem cells 
and leukemia.
Sandeep Joshi, Ph.D. 
– Dr. Joshi earned his 
Ph.D. in May 2010 
under the mentorship 
of Dr. Richard M. Niles. 
He is working as a 
Postdoctoral Fellow 
in the Dermatology 
Branch, National 
Cancer Institute, 
National Institutes of 
Health in Bethesda, Maryland. His research 
area is pigment cell biology and melanoma.
Lauren Richards-
Waugh, Ph.D. – 
Dr. Richards-Waugh 
earned her Ph.D. 
in May 2010 under 
the mentorship of 
Dr. Gary O. Rankin. 
She is working as 
Forensic Toxicologist 
at The West Virginia 
Office of the Chief 
Medical Examiner 
in Charleston, and lectures for the 
Drug Enforcement Administration in 
their Pharmaceutical Overdose Death 
Investigation seminar series.
Jennifer Napper, 
Ph.D. – Dr. Napper 
earned her Ph.D. in 
August 2010 under 
the mentorship of 
Dr. Vincent E. Sollars. 
She is working as 
Biology Instructor at 
Ashland Community 
and Technical 
College, and teaches 
Anatomy and Physiology 
in Ashland, Kentucky.
8P,)T]UVQ R E C E N T  G R A D U A T E SOther Employers
of our Alumni
“They care a
bout their st
udents, and
 this really c
omes 
across. The i
ndividual at
tention to st
udents is ex
traordinary
 
and much d
i"erent than
 what you w
ould #nd in 
other 
programs. I 
think this se
ts up BMS g
raduates we
ll 
for success.” — George Ka
mphaus, Ph
.D., Senior S
cientist 
for Syntonix 
Pharmaceut
icals and an 
alumnus of t
he BMS, Ph.D
. program
Applied Biosystems
East Ohio Regional Hospital
Federal Bureau of Investigation
Kent University
L’Oréal
Long Island Jewish Medical Center
Morehead State University
Progenesis Technologies, LLC
Rite Aid Pharmacy
Syntonix Pharmaceuticals, 
a subsidiary of Biogen Idec
University of Alabama 
at Birmingham
University of Charleston 
School of Pharmacy
University of Hawaii at Manoa
University of Kentucky 
Graduate Center for Toxicology
University of North Carolina 
at Wilmington
University of Virginia
Wheeling Jesuit University
Wil Research Laboratories
Zymed Laboratories
F I N A N C I A L  S U P P O R T
The BMS Graduate Program continues to thrive, but is always seeking ways to make improvements for its students. Your #nancial contribution 
will support BMS Ph.D. students via scholarships/stipends or fund students’ travel to biomedical meetings. Financial support can also be 
given to strengthen and expand the Biomedical Sciences Summer Research Internship for Minority Students.  
Contributions of any amount are both helpful and appreciated!
To contribute to the BMS Graduate Program Fund or the SRIMS Program Fund, visit: http://www.marshall.edu/foundation/givenow.php 
or complete and submit the form below.
YES! I will support the Marshall University BMS Graduate Program.
o BMS Graduate Education Development Fund (213078)  o Biomedical Summer Research Internship (213073)
I’ve/We’ve enclosed $
Please charge my gift of $ to:
o Visa      o Mastercard      o American Express      o Discover
Card Number            Exp. Date
Signature
Name
Address
City           State                  Zip
Email
Home Phone (      )      Cell Phone (          )      
o My employer will match any gift.
Company
Company Phone (           ) 
Company Address  
Please make your check payable to The Marshall University Foundation, Inc., and indicate the 
BMS Graduate Program Fund (213078) or the SRIMS Program Fund (213073) on the memo line.
Please mail contributions to:
The Marshall University Foundation, Inc.
519 John Marshall Drive
Huntington, West Virginia 25705
You can also make contributions at: http://www.marshall.edu/foundation/givenow.php. <PIVSAW]	
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A B O U T  T H E  P R O G R A M  |  F A Q ’ S
Q:  What is the purpose of the Biomedical Sciences (BMS) graduate 
education fund?
A:  To award competitive scholarships to BMS Ph.D. students and fund 
travel to regional and national biomedical meetings where students 
can present their research.
Q:   What is the purpose of the SRIMS program fund?
A:  To enrich the students’ research and overall internship experiences.
Q:  What degree programs are currently o#ered by the Biomedical 
Sciences (BMS) Graduate Program?
A:   There are currently three degree programs: the Ph.D. in Biomedical 
Sciences, the Master of Science in Biomedical Sciences (research-
based, thesis requirement), and the Master of Science in Biomedical 
Sciences with an area of emphasis in medical sciences (non-research, 
no thesis requirement). The medical sciences program is geared 
toward students who intend to apply to medical school or pursue a 
career in health professions such as the allied health sciences, or in 
non-research positions. 
Q:  What areas of emphasis are available in the BMS Ph.D. and M.S. 
(thesis) programs?
A:  There are #ve (5) research clusters: Cancer Biology; Cardiovascular 
Disease, Obesity and Diabetes; Infectious and Immunological 
Diseases; Neuroscience and Developmental Biology; and Toxicology 
and Environmental Health Sciences. 
Q:  What is the enrollment size of the Ph.D. program?
A:  The current total enrollment is approximately 30, but enrollment 
depends on the funding available and the number of students 
graduating in a particular year. Please contact the Graduate 
Recruitment and Communication Coordinator Diana Maue 
 (maue1@marshall.edu) for more information about admissions.
Q:  How are Ph.D. students funded?
A:   Ph.D. students are funded by the BMS program for their #rst 
 two years. Beginning the third year, the program provides 
 50 percent of the funding and students work with their advisors 
and granting agencies to fund the other half of the stipend.
Q:  What is the current stipend for a Ph.D. student? Are any 
other bene$ts provided?
A:   The current stipend for a Ph.D. student is $23,000/year in 
addition to tuition remission. Students have access to 
 Marshall University’s Student Health Service, which provides 
healthcare services to students in the case of acute illness, 
including diagnosis, laboratory and radiographic procedures.
Q:  Are graduate assistantships available to research 
 master’s students?
A:   The BMS Program does not provide graduate assistantships 
 for its Master’s students. 
Q:  What is the enrollment size of the medical sciences 
 area of emphasis program?
A:  The program is limited to about 15 students who enter each fall. 
The class can #ll up quickly, so get your application in early!
Q:  How do students pursuing a research master’s degree 
 or Ph.D. choose their lab?
A:  During the #rst year of the M.S. (thesis) and Ph.D. programs, 
students are required to complete rotations through a minimum 
of three di!erent laboratories. Each rotation consists of about 
 40 hours. Students should select a laboratory and form an 
advisory committee no later than the end of the #rst year of 
graduate education.
w w w . b m s . m a r s h a l l . e d u
O+ce of Research and Graduate Education
Biomedical Sciences Graduate Program
Byrd Biotechnology Science Center
Marshall University
One John Marshall Drive
Huntington, West Virginia 25755-2195-127
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